Mechanisms involved in the contractile responses of kinins in rat portal vein rings: mediation by B1 and B2 receptors.
This study investigates the mechanisms involved in kinin-induced contractions in rings of rat portal vein (RPV). Bradykinin (BK), Lys-BK, Met-Lys-BK, Tyr8-BK (TBK) and des-Arg9-BK (DABK) all caused graded contractions in RPV, with the following order of potency (EC50, nanomolar): Met-Lys-BK (0.3) > Lys-BK (0.5) > BK (0.9) > TBK (2.3) >> DABK (46.0). The potency of DABK and maximal contractions for DABK and BK, but not for TBK or NE, increased as a function of in vitro incubation period, reaching the maximum at 4.5 hr. Cycloheximide (a protein synthesis inhibitor, 70 microM), incubated for 4.5 hr, inhibited almost completely the CRCs for DABK and blocked the latter phase of CRCs for BK, not altering contractions induced by U46619 (9,11-dideoxy-9 alpha, 11 alpha-methano-epoxy prostaglandin F2 alpha) (a thromboxane A2/prostaglandin H2-mimetic). Incubation of RPV with D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]-BK (HOE 140, a selective B2 receptor antagonist, 0.01-100 nM), caused a parallel rightward displacement of the BK and TBK concentration-response curves (CRCs). Schild plots were linear, yielding pA2 values of 11.4 and 9.3, respectively. The slope for HOE 140 against TBK-induced contractions did not differ from unity (1.23 +/- 0.21), whereas against BK was significantly lesser than unity (0.72 +/- 0.20). The CRCs induced by DABK were not affected by HOE 140 (100 nM). In addition, the CRCs for DABK at 4.5 hr were shifted to the right in a parallel form in the presence of des-Arg9-[Leu8]-BK (a selective B1-receptor antagonist, 1 microM), yielding a pA2 value of 6.7.(ABSTRACT TRUNCATED AT 250 WORDS)
Campos
A H
AH
Department of Pharmacology, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Calixto
J B
JB
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology*; D003513:Cycloheximide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D011169:Portal Vein / Q000187:drug effects* / Q000502:physiology; D011450:Prostaglandin Endoperoxides, Synthetic / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018002:Receptors, Bradykinin / Q000502:physiology*; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects*
D007093:Imidazoles; D007211:Indoles; D011450:Prostaglandin Endoperoxides, Synthetic; D018002:Receptors, Bradykinin; C029166:dazoxiben; C052517:L 655240; D013928:Thromboxane A2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; C065679:icatibant; D003513:Cycloheximide; D001920:Bradykinin; D009638:Norepinephrine